Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit...

Area of Science:

• Microbiology
• Immunology
• Drug Discovery

Background:

• Tuberculosis (TB) remains a significant global health challenge despite being discovered over a century ago.
• Key factors contributing to TB's persistence include increasing drug resistance, poor patient compliance, and the bacterium's ability to enter a long-term asymptomatic latent state.
• Current TB therapies are often ineffective against this latent form, hindering complete infection clearance.

Purpose of the Study:

• To review current therapeutic and diagnostic approaches for tuberculosis.
• To explore methods for mimicking the latent state of tuberculosis in experimental settings for drug discovery.
• To identify and discuss novel drug targets and compounds in development for combating TB latency.

Main Methods:

• Compilation of existing literature on tuberculosis therapies and diagnostics.
• Review of experimental in vitro and in vivo models used to simulate TB latency.
• Analysis of studies focusing on specific molecular targets and chemical scaffolds for latent TB drug discovery.

Main Results:

• Identification of limitations in current TB treatments, particularly against the latent form.
• Overview of various experimental models designed to replicate TB latency, with varying complexity.
• Highlighting of promising molecular targets and drug candidates emerging from latency-focused research.

Conclusions:

• Addressing the challenge of tuberculosis latency is paramount for disease eradication.
• The development of novel drugs and therapeutic strategies targeting the latent state is essential.
• Continued research into latency mechanisms and new drug discovery pipelines offers hope for overcoming TB persistence.